The FDA approved delgocitinib (Anzupgo®), a topical pan‑JAK inhibitor, for adults with chronic hand eczema who failed topical corticosteroids or cannot use them. Regulators emphasized the topical formulation’s lower systemic exposure compared with oral JAK inhibitors, citing an acceptable safety profile in pivotal studies. The approval adds a targeted non‑systemic JAK option to dermatology and will influence prescribing patterns and payer coverage decisions. Manufacturers and clinicians will monitor post‑marketing safety communication given class‑wide boxed warnings for systemic JAK inhibitors.